Maropitant

The clinical demand for antiemetics for pets has long been in a state of not being fully met, especially the management and control of chemotherapy-related vomiting, transportation stress-induced vomiting and postoperative vomiting, which has a particularly significant impact on the quality of life of pets. Maropitant is an antiemetic drug belonging to the neurokinin-1 (NK-1) receptor antagonist class. By selectively blocking the binding of substance P in the central and peripheral regions to NK-1 receptors, it exerts an inhibitory effect from the terminal pathway of the vomiting reflex. It is currently one of the few pet-specific active pharmaceutical ingredients that can be used for the control of both central and peripheral vomiting. Its scope of application covers common companion animals such as dogs and cats, and it can prevent and treat various types of pet vomiting symptoms such as acute vomiting and motion vomiting. It has a low incidence of adverse reactions and excellent clinical safety performance.

The size of the global pet veterinary drug market continues to expand. In 2023, the market size of pet antiemetic drugs has exceeded 1.2 billion US dollars, with a compound annual growth rate maintained at around 8.7%. As a core drug in the field of pet antiemesis, maropitant has consistently ranked among the top pet antiemetic drugs in terms of market share over the years. The United States and Europe are the main consumer markets, accounting for more than 65% of the total global demand. The domestic pet medical market has entered a period of explosive growth in recent years, and the growth rate of demand for maropitant preparations has exceeded 20% for three consecutive years. At present, the maropitant preparations marketed in China are still mainly original research products, the number of generic drug applications is small, and the supply gap of active pharmaceutical ingredients is relatively obvious.

The original research enterprise of maropitant is Zoetis Inc. in the United States, and the original research trade name is "Cerenia". The expiration time of its core compound patent in the United States is 2023, and the expiration time of the European patent is 2024. The main dosage forms approved by the original research include injections and tablets. Common specifications are 16mg, 24mg, 60mg, 160mg tablets and 10mg/ml injections. The original research preparations have been included in the FDA Reference Listed Drug Catalog. In terms of the domestic market, at present, the maropitant active pharmaceutical ingredients of a number of enterprises have completed registration with the CDE, and at the same time, 2 domestic maropitant tablets and 1 injection have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of maropitant impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for all links of veterinary drug research and development, quality research and production quality control.